



COUNTY OF SAN LUIS OBISPO HEALTH AGENCY
PUBLIC HEALTH DEPARTMENT
PROVIDER HEALTH ADVISORY

Date: August 19, 2022

Contact: Rick Rosen, MD, MPH, 805-781-5500, frosen@co.slo.ca.us

Preliminary JYNNEOS Vaccine Appointments

Providers asked to refer patients with moderate to severe immune compromise who are currently at increased risk for monkeypox (MPX) infection

Following the identification of the first case of monkeypox (MPX) in San Luis Obispo County, the Public Health Department has received a small increase in supply of JYNNEOS vaccine, which provides protection against MPX and smallpox. In addition, the FDA has authorized intradermal injection as a way to vaccinate more people with limited vaccine supply.

As a result, the Public Health Department is able to expand vaccine eligibility to a small number of patients at highest risk for severe outcomes from MPX infection. These preliminary appointments are available by healthcare provider referral, in advance of wider availability to the public.

Expanded eligibility criteria

Vaccine continues to be prioritized for people who have had close contact with a confirmed case of MPX (PEP). In addition, we ask that healthcare providers refer patients age 18 and older who are facing high risk from MPX and meet the following criteria (at least one from each column):

<p>Meets at least one of these criteria:</p> <p>Identify as gay, bisexual, or other men or trans people who have sex with men</p> <p>Sex workers of any sexual orientation or gender identity and anyone who engages in transactional or survival sex</p>	<p>AND at least one of these criteria:</p> <p>HIV infection</p> <p>Receiving active cancer treatment for tumors or cancers of the blood</p> <p>Received an organ transplant and are taking medicine to suppress the immune system</p> <p>Moderate or severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome)</p> <p><i>(continued on next page)</i></p>
--	--

	<p>Active treatment with high-dose corticosteroids or other drugs that may suppress their immune response</p> <p>Received chimeric antigen receptor (CAR)-T-cell therapy (a treatment to help immune system attach to and kill cancer cells) or received a stem cell transplant (within the last 2 years)</p>
--	---

Because vaccine supply remains inadequate at a state and national level, it is possible that someone may meet these eligibility criteria but be unable to receive a vaccine immediately. The goal is for everyone who wants a vaccine to receive a vaccine. We will keep healthcare providers and the community informed as more doses become available.

Considerations for patients

While intradermal JYNNEOS vaccine is safe and effective, it is not without considerations for patients at this stage in the MPX outbreak. Please communicate these important considerations to patients prior to formally referring them for vaccination:

- **Reactions at the injection site are common with intradermal vaccination.** Intradermal immunization can result in local inflammation at the site of injection more frequently than after subcutaneous or intramuscular immunization, occurring in nearly all trial participants who received intradermal MPX vaccine, and many who received licensed intradermal seasonal influenza vaccine. 36% of trial participants who received intradermal MPX vaccine had mild injection site induration, erythema, or discoloration lasting at least 6 months. [See detail from the California Department of Public Health.](#)
- **Jynneos is a two-dose series, with first doses currently prioritized.** JYNNEOS is a two-dose series, with the second dose administered at least four weeks after the first. (A person is considered fully vaccinated 14 days after the second dose.) Because of the current vaccine scarcity relative to need, state guidance strongly recommends prioritizing first doses. It is likely that patients who receive a first dose through these initial appointments may experience a delay in receiving the second dose.
- **Patients with a history of keloid scar formation are NOT recommended to receive intradermal vaccine injections.** If you have a patient who otherwise meets eligibility criteria and has a history of keloid scar formation, please note this in your referral.
- **Patients may wish to consider personal factors in deciding when to get vaccinated.** Increased vaccine access should allow opportunities for subcutaneous (not only intradermal) vaccination in the next 6-12 months. In addition, patients who have been vaccinated against smallpox likely have some protection against MPX and may wish to defer vaccination until access expands.

Process for vaccination

1. **Consult with patients.** Please confer with patients who may be eligible for vaccination to discuss the relevant considerations (above) and confirm their interest and phone number.
2. **Submit referral.** Please complete the attached referral form and fax to **805-781-5543**. If you wish to confirm receipt of the fax, please contact Alex Guill, Clinic Manager, at 805-788-5500 or aguill@co.slo.ca.us.
3. **Public Health will contact patient to schedule.** The Public Health team will call the patient to schedule an appointment.
4. **Patients will receive instructions on how to follow up regarding second doses.**
5. **As vaccine supply increases, any patients who meet eligibility criteria but were unable to schedule an appointment right away will be contacted by Public Health to schedule their first dose appointments.**

Vaccine fact sheets

- CDC Vaccine Information Statement: Smallpox/Monkeypox Vaccine (JYNNEOS): What You Need to Know: www.cdc.gov/vaccines/hcp/vis/vis-statements/smallpox-monkeypox.pdf
- FDA Fact Sheet for Recipients and Caregivers on JYNNEOS: <https://www.fda.gov/media/160773/download>

To stay informed

Healthcare providers will continue to receive updates via advisories like this one. Local residents may sign up to receive updates on monkeypox, including announcements when vaccine access expands, at slocounty.ca.gov/mpx.

To report suspected cases

Call the San Luis Obispo County Public Health Department as soon as possible. Call 805-781-5500 (M-F, 8 a.m.–5 p.m.) or 805-781-4553 (weekends and after hours).

For more information on MPX

- SLO County Public Health Monkeypox Information: slocounty.ca.gov/mpx
- SLO County Public Health Laboratory testing information: slocounty.ca.gov/lab-news
- CDPH Monkeypox page: www.cdph.ca.gov/Programs/CID/DCDC/Pages/monkeypox.aspx
- CDC Monkeypox Information for Healthcare Professionals: www.cdc.gov/poxvirus/monkeypox/clinicians/index.html

Preliminary JYNNEOS Vaccine Appointment Referral

Healthcare provider name:

Healthcare provider phone number:

Patient name:

Patient phone number(s):

Does patient have a history of keloid scar formation?

yes no

Has patient previously been vaccinated against smallpox or MPX?

yes no

Does patient meet eligibility criteria as defined in the attached advisory?

yes no

Has healthcare provider discussed patient considerations as described in the attached advisory?

yes no

Please provide any additional notes here:

Please fax this form to **805-781-5543**.

(If you wish to confirm receipt of the fax, please contact Alex Guill, Clinic Manager, at 805-788-5500 or aguill@co.slo.ca.us.)